Checkmate K9: groundbreaking immunotherapy for canine cancer

University of Wisconsin researchers have taken a historic step: the first combination immunotherapy in dogs with solid tumors, inspired by advances in human oncology.

Introduction – A new era for veterinary oncology
Until recently, dogs with cancer were primarily dependent on surgery and chemotherapy, often with severe side effects. The rise of immunotherapy in humans—which activates the body's own immune system to attack cancer cells—is now inspiring veterinary pioneers. "Checkmate K9," launched in 2025, is the first clinical trial to combine two monoclonal antibodies (anti-cCTLA-4 and anti-cPD-1) in dogs with solid tumors. This article discusses the design, initial results, and what this means for dogs and their owners.

What is immunotherapy?
Immunotherapy works by blocking inhibitory checkpoints in the immune system, so that T cells are no longer inhibited by tumors. In humans, the combination of anti-CTLA-4 and anti-PD-1 has led to clear treatment successes for various cancers. Checkmate K9 translates this mechanism into veterinary practice.

Research design of Checkmate K9

• Participant selection : Dogs with malignant solid tumors, including mast cell tumors and melanoma, selected based on age, general health and life expectancy.
• Dosing : The first participant received an initial infusion of both antibodies, followed by booster treatments to promote safe remission.
• Monitoring : Clinical monitoring includes imaging (CT/MRI), blood tests and evaluation of adverse events according to Veterinary Cooperative Oncology Group (VCOG) criteria.

First results and safety
Although the study is still in its early stages, researchers are reporting positive signs: the first patient demonstrated a stable tumor response after four weeks with minimal side effects (mild fever and loss of appetite). This aligns with human data, in which a combination of checkpoint inhibitors slows tumor growth without the toxicity of conventional chemotherapy.

Benefits for dogs and owners

1. Targeted treatment : fewer off-target effects and better quality of life.
2. Potential for long-term remission : Immunological memory effects may slow backsliding.
3. New options : for breeds and tumor types that respond poorly to surgery and chemo.

Practical considerations

• Cost : Immunotherapy has been more expensive than traditional treatments so far; required insurance and financing models are under development.
• Accessibility : Currently limited to specialized university clinics.
• Co-payment : Owners may consider clinical trials – often reimbursed by research grants.

Checkmate K9's role in One Health
The line between human and veterinary medicine is blurring. Successful veterinary immunotherapy leads to:

• Cross-over study data : insights into dosage and side effects.
• Accelerating human trials : Dog data provides new impetus for humans.
• Shared infrastructure : sharing lab facilities and datasets.

Future and advice for owners
Checkmate K9 is expanding to include dozens of participants by the end of 2025. Owners with eligible dogs can contact the UW Veterinary School. Good preparation is crucial:

• Have medical records on hand.
• Open discussion about goals and expectations.
• Support by specialist veterinarians and, if necessary, emotional support.

Conclusion – immunotherapy for dogs as a game changer
Checkmate K9 marks a crucial turning point in veterinary oncology. By translating successful human models to dogs, a new treatment horizon opens up: targeted, less invasive, and potentially life-extending. While initial results are encouraging, rigorous research remains essential. Owners are now faced with the possibility of advanced care: no longer purely palliative, but focused on remission and quality of life. The future of canine cancer treatment is here—and it starts with immunotherapy.